An Open-Label, Phase 2 Study to Treat Patients With Renal Allograft and Polyoma BK Viruria to Prevent Polyoma BK Viremia, Polyoma BK Nephropathy and Renal Allograft Rejection

Trial Profile

An Open-Label, Phase 2 Study to Treat Patients With Renal Allograft and Polyoma BK Viruria to Prevent Polyoma BK Viremia, Polyoma BK Nephropathy and Renal Allograft Rejection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Leflunomide (Primary) ; Orotic acid (Primary)
  • Indications Kidney disorders; Polyomavirus infections; Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Chang Zheng-Cinkate Pharmaceutical Corporation
  • Most Recent Events

    • 25 Jul 2016 Planned end date changed from 1 Apr 2016 to 1 Mar 2018.
    • 25 Jul 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
    • 21 May 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top